« Back to Record
Citation APA

Baselga, J., Ito, Y., Awada, A., Chia, S., Jagiełło-Gruszfeld, A., Pistilli, B., Tseng, L. M., Hurvitz, S., Masuda, N., Takahashi, M., Vuylsteke, P., Im, S. A., Hachemi, S., Dharan, B., Di Tomaso, E., Urban, P., Massacesi, C., Campone, M., Iwata, H., Cortes, J., De Laurentiis, M., Jiang, Z., Arteaga, C. L., Jonat, W., & Clemons, M. J. (2017). Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet oncology, 18(7), 904-916. doi:10.1016/S1470-2045(17)30376-5


Permalink

http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/259266

Baselga, J., Ito, Y., Awada, A., Chia, S., Jagiełło-Gruszfeld, A., Pistilli, B., Tseng, L. M., Hurvitz, S., Masuda, N., Takahashi, M., Vuylsteke, P., Im, S. A., Hachemi, S., Dharan, B., Di Tomaso, E., Urban, P., Massacesi, C., Campone, M., Iwata, H., Cortes, J., De Laurentiis, M., Jiang, Z., Arteaga, C. L., Jonat, W., & Clemons, M. J. (2017). Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet oncology, 18(7), 904-916. doi:10.1016/S1470-2045(17)30376-5